KPV
Coverage of KPV in the Nexus archive.
- FDA panel overrules its own scientists to ease access to unproven peptide injections
The FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend four unproven peptides (BPC-157, KPV, TB-500, and MOTS-c) for access through compounding pharmacies, despite scientific concerns.
- FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to add peptides like BPC-157, KPV, TB-500, and MOTS-c to the list of substances compounding pharmacies can make, despite opposition from FDA scientists over concerns about their unproven benefits.
- US health panel recommends easing restrictions on controversial peptides
A US federal health advisory panel recommended easing restrictions on peptides like BPC-157, TB-500, and KPV, despite warnings from government scientists about their safety and effectiveness. The panel includes members linked to the peptides industry, and the decision may influence RFK Jr.'s stance.
- US health panel recommends easing restrictions on controversial peptides
A US health panel recommended easing restrictions on peptides like BPC-157, TB-500, and KPV, despite government scientists' warnings about their safety and effectiveness. The panel includes members linked to the peptides industry, and the decision may influence RFK Jr.
- FDA Panel Narrowly Backs Lifting Restrictions on Peptides Backed by RFK Jr.
An FDA advisory committee voted to remove compounding restrictions on peptides BPC-157 and KPV, despite limited evidence of their safety or effectiveness for medical use. The decision was backed by RFK Jr., who promotes these peptides as wellness products.